NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

Published:2022-03 Issue:3 Volume:20 Page:224-234
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Caudell Jimmy J.¹,Gillison Maura L.²,Maghami Ellie³,Spencer Sharon⁴,Pfister David G.⁵,Adkins Douglas⁶,Birkeland Andrew C.⁷,Brizel David M.⁸,Busse Paul M.⁹,Cmelak Anthony J.¹⁰,Colevas A. Dimitrios¹¹,Eisele David W.¹²,Galloway Thomas¹³,Geiger Jessica L.¹⁴,Haddad Robert I.¹⁵,Hicks Wesley L.¹⁶,Hitchcock Ying J.¹⁷,Jimeno Antonio¹⁸,Leizman Debra¹⁴,Mell Loren K.¹⁹,Mittal Bharat B.²⁰,Pinto Harlan A.¹¹,Rocco James W.²¹,Rodriguez Cristina P.²²,Savvides Panayiotis S.²³,Schwartz David²⁴,Shah Jatin P.⁵,Sher David²⁵,St. John Maie²⁶,Weber Randal S.²,Weinstein Gregory²⁷,Worden Frank²⁸,Yang Bruce Justine²⁹,Yom Sue S.³⁰,Zhen Weining³¹,Burns Jennifer L.³²,Darlow Susan D.³²

Affiliation:

1. 1Moffitt Cancer Center;

2. 2The University of Texas MD Anderson Cancer Center;

3. 3City of Hope National Medical Center;

4. 4O'Neal Comprehensive Cancer Center at UAB;

5. 5Memorial Sloan Kettering Cancer Center;

6. 6Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

7. 7UC Davis Comprehensive Cancer Center;

8. 8Duke Cancer Institute;

9. 9Massachusetts General Hospital Cancer Center;

10. 10Vanderbilt-Ingram Cancer Center;

11. 11Stanford Cancer Institute;

12. 12The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

13. 13Fox Chase Cancer Center;

14. 14Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

15. 15Dana-Farber/Brigham and Women’s Cancer Center;

16. 16Roswell Park Comprehensive Cancer Center;

17. 17Huntsman Cancer Institute at the University of Utah;

18. 18University of Colorado Cancer Center;

19. 19UC San Diego Moores Cancer Center;

20. 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

21. 21The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute;

22. 22Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

23. 23Mayo Clinic Cancer Center;

24. 24St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

25. 25UT Southwestern Simmons Comprehensive Cancer Center;

26. 26UCLA Jonsson Comprehensive Cancer Center;

27. 27Abramson Cancer Center at the University of Pennsylvania;

28. 28University of Michigan Rogel Cancer Center;

29. 29University of Wisconsin Carbone Cancer Center;

30. 30UCSF Helen Diller Family Comprehensive Cancer Center;

31. 31Fred & Pamela Buffett Cancer Center; and

32. 32National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/3/article-p224.xml

Reference184 articles.

1. Role of HPV 16 variants among cervical carcinoma samples from Northeastern Brazil;da Silva;BMC Womens Health,2020

2. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial;Nichols;Lancet Oncol,2019

3. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma;Chera;J Clin Oncol,2019

4. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial;Gillison;Lancet,2019

5. Human papillomavirus and survival of patients with oropharyngeal cancer;Ang;N Engl J Med,2010

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perineural invasion is a poor prognostic factor for sinonasal squamous cell carcinoma;Oral Oncology;2024-03

2. Extra-Capsular Spread of Lymph Node Metastasis in Oral, Oropharyngeal and Hypopharyngeal Cancer: A Comparative Subsite Analysis;Cancers;2024-02-03

3. A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ALARM” study;Cancer Medicine;2024-01-21

4. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma;Journal of Clinical Oncology;2024-01-19

5. Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes;Journal of Clinical Oncology;2024-01-10